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Abstract DNA uptake can be facilitated by addition of 
physiological amounts of llß-hydroxy glucocorticosteroids (such 
as cortisol) during transfection. In the presence of cortisol, but 
not of the inactive 11-keto glucocorticoid cortisone, twice as 
many cells uptake and express the reporter gene. The effect is 
specific and dose-dependent; the amounts of glucocorticosteroids 
needed to enhance transfection efficiency are in the nanomolar 
range, which corresponds to the dissociation constant of 
glucocorticoids for the glucocorticoid receptor in vitro. This 
effect can be abolished by an excess of the glucocorticoid 
antagonist RU486. We infer that the activated cytoplasmic 
glucocorticoid receptors enhance nuclear translocation of the 
incoming transfected DNA. 
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1. Introduction 
The use of gene therapy to treat genetic diseases has in-
creasingly become the focus of research. The ideal delivery 
system should have at least the following characteristics: the 
ability to target cells effectively, the ability to transduce a 
large number of cells regardless of their mitotic status, and 
the potential to be synthetic and of low toxicity. Several de-
livery systems have been designed based on either recombi-
nant viruses or non-viral vectors [1]. A recurrent problem, 
however, is the relative poor efficiency of nuclear transloca-
tion of the foreign DNA from the cytoplasm to the nucleus 
[2,3]. Even if the efficiency with which the DNA-vehicle for-
mulation crosses the cellular membrane is relatively high, and 
even if the release of the exogene complex from the endosome 
is efficient, only a fraction of the DNA actually reaches the 
nucleus. One way to solve this problem is to include in the 
delivery system peptides that contain a nuclear localisation 
signal [4-6]. This approach has advantages and disadvantages. 
The obvious advantage is a much improved nuclear translo-
cation. The major disadvantage is the relative lack of versa-
tility. Having to introduce a nuclear peptide in the delivery 
system may severely limit the choice of the vehicle and may 
involve complicated chemical linkage steps. In turn, this can 
limit the choice of delivery systems that ensure target specific-
ity, which is usually related to the type of vehicle used [7]. 
With this regard, the use of a nuclear translocation system 
that does not influence the versatility of vehicles and at the 
same time can be used in a wide variety of cells would be 
extremely advantageous. 
We asked whether cytoplasmic steroid receptors could im-
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prove the efficiency of transfection. Cytoplasmic glucocorti-
coid receptors become activated by incoming llß-hydroxy 
glucocorticosteroids, translocate to the nucleus and bind 
DNA sequence specifically [8-10]. We reasoned that if gluco-
corticoid receptors can be activated and meet a transfected 
DNA directly in the cytoplasm, they might bind the exogene 
(which if long enough will contain glucocorticoid-binding se-
quences) and carry it to the nucleus, thus improving trans-
fection efficiency. Moreover, glucocorticoid receptors are 
ubiquitous, and a positive result in this direction may provide 
a useful tool for improving transfection efficiency of a wide 
variety of cells. 
2. Material and methods 
2.1. Cell culture 
3Y1 cells [11] and HeLa cells were cultured in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 10% FCS (PAA Labo-
ratories, Linz, Austria) at 37°C under 5% СО2. 
2.2. Glucocorticoid receptor-binding assays 
For binding assays, cells were harvested and lysed in a hypotonic 
buffer (10 mM Tris pH 7.5/10 mM NaCl/1 mM EDTA/10% glycerol/ 
10 mM sodium molybdate/10 mM ß-mercaptoethanol) in a dounce 
homogeniser (B-pestel). The cell extract was centrifuged at lOOOOXg 
for 1 h, and the protein concentration adjusted to 0.6 mg/ml. One 
hundred μΐ (60 μg, corresponding to the extract about 2X106 cells) 
were used for each sample. The samples were incubated in the same 
buffer but with 100 nM NaCl in presence of 10 pmoles [1,2,4-
3H]dexamethasone (2X1017 dpm/mole) and increasing amounts of 
unlabelled steroid competitors (1-1000-fold excess) on ice for 2 h. 
The reaction was stopped by addition of active charcoal to a final 
concentration of 20 mg/ml to absorb excess, unbound steroids. The 
supernatant was spotted onto glass microfibre filters (Whatman 1822-
025) and washed extensively in 20 mM Tris pH 8, 1 mM EDTA, 
40 mM NaCl. The filters were patted dry, introduced in counting 
vials with Irga-safe-plus scintillation fluid (Packard) and counted in 
a Packard beta-counter. 
2.3. Plasmids, transfection protocol, and X-gal staining 
The CMV-LacZ reporter plasmid consists of the bacterial ß-galac-
tosidase gene under control of the cytomegalovirus promoter in a 
pUC18 background. For transfection, 5 μg CMV-lacZ plasmid 
DNA were mixed with 20 pmoles cortisol, 20 pmoles cortisone or 
an equivalent amount of solvent (ethanol) in 500 μΐ TBS. For com-
petition experiments, 20 nM cortisol was used with the addition of 
20 μΜ RU486, a glucocorticoid antagonist. 
After incubation at room temperature for 15 min, 500 μΐ of a 
solution of 10 μg/ml polyethyleneimine (PEI) in TBS was added drop-
wise to the DNA/steroid mixture. This PEI solution was prepared by 
diluting 100 μΐ PEI Stock in 10 ml TBS, where the stock consists of 
90 mg PEI (50% aq. sol., 50 000 kDa, Sigma) in 50 ml H20 [12]. The 
DNA-steroid-PEI complex (1 ml, final steroid concentration 20 nM) 
was overlaid directly onto 3Y1 cells (in 6 cm dishes, 50% confluent) 
which had been rinsed twice with TBS. The cells were then incubated 
at room temperature for 3^1 h. The mixture was then removed, and 
3 ml of fresh medium (without steroids) was added. 
After a 3 day culture, the cells were washed twice with cold PBS 
supplemented with 2 mM MgCb and fixed in ice-cold PBS/2 mM 
MgCl2/2% formaldehyde/0.5%) glutaraldehyde at 4°C for 15 min. 
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The cells were subsequently rinsed with PBS/2 mM MgCb and stained 
with PBS/2 mM MgCl2/0.05% NP40/5 mM K3[Fen(CN)6]/5 mM 
K4[Feln(CN)6]. A fixed area of the dishes was then examined micro-
scopically, and the number of blue cells was determined. 
3. Results and discussion 
3.1. Choice of model system 
To test whether llß-glucocorticosteroids can enhance 
through the glucocorticoid receptor (GR) the efficiency of 
transfection, we first looked for an appropriate model system. 
In the ideal system, the number of incognita would have to be 
minimised, in particular it should consist of cells that express 
reasonable levels of glucocorticoid receptor. Only thus an in-
equivocable proof of principle can be obtained, and the model 
can be subsequently extended to other cell types. 
Normally, mammalian cell extracts do not contain enough 
glucocorticoid receptor to yield any measurable binding of 
radiolabelled glucocorticoids, unless the cells are transfected 
with a GR expression vector. In contrast, rat 3Y1 cells [11] 
contain levels of GR high enough to yield significant and 
specific binding. As shown in Fig. 1, 60 μg of 3Y1 cell extracts 
(the equivalent of about 2 x 106 cells) reproducibly bind about 
50 fmoles of [l,2,4-3H]dexamethasone (2x l0 1 7 dpm/mole). 
From these data, we calculated that 3Y1 contain about 
20000 GRs per cell. The binding is specific, because it can 
be competed efficiently by an excess of non-labelled dexameth-
asone. Less active steroids can do so only less efficiently; for 
instance, the inhibition constant (IC50) of cortisol-21-hemi-
succinate is 10-fold higher than that of cortisol (data not 
shown). 
3.2. 11 ß-glucocorticoids enhance transfection efficiency 
of3Yl cells 
We tested the effect of steroids on the transfection efficiency 
of 3Y1 cells using a reporter plasmid, CMV-LacZ, which car-
ries the bacterial ß-galactosidase gene under the control of the 
human cytomegalovirus promoter. Five μg DNA were trans-
fected by the polyethyleneimine method [12] or the calcium 
phosphate method to 3Y1 cells in 6 cm dishes in the absence 
of steroids, with 20 nM cortisone or 20 nM cortisol (the active 
l lß-OH form). Cortisone is an 11-keto compound; it cannot 
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Fig. 1. Estimate of GR content in 3Y1 cells based on specific bind-
ing of [3H]dexamethasone. Sixty μg of 3Y1 cell extracts, correspond-
ing to the extract of about 2xl06 cells, were incubated with 
10 pmoles [l,2,4-3H]dexamethasone (2X1017 dpm/mole) and increas-
ing amounts of unlabelled steroid competitors (1-1000-fold molar 
excess), and binding activity was determined as described in Section 
2. Three independent determinations are displayed. 
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Fig. 2. Cortisol enhances transfection efficiency of 3Y1 cells. Five 
μg CMV-lacZ plasmid DNA were mixed with 20 pmoles cortisol, 
20 pmoles cortisone or an equivalent amount of solvent (ethanol) 
and transfected to 3Y1 cells by the polyethileneimine method (PEI) 
[12] (see Section 2). We also performed experiments with the calci-
um phosphate method to verify that the results are reproducible 
under various conditions. Transfection efficiency of each sample was 
represented as the percent of control. The results shown in this fig-
ure represent the mean±S.E.M. from six independent experiments, 
of which one was carried out with the calcium phosphate method 
(with similar results). 
bind the glucocorticoid receptor and is therefore inactive. 
Cortisol, in contrast, is an llß-hydroxy compound and has 
full steroid activity. 
If cortisol influences transfection in a positive way, more 
cells should express the reporter gene in its presence. How-
ever, this effect, if observed, may be explained in several ways. 
On one hand, it is possible that steroids do not influence how 
much exogene is internalised and transferred to the nucleus. 
Similar amounts of the exogene may reach the nucleus of 3Y1 
cells, but only in those cells exposed to cortisol transcription 
may be unspecifically enhanced, so that the threshold of ex-
pression of the transfected ß-galactosidase may be more easily 
reached. This hypothesis is nominally possible, but is unlikely. 
First, there are no reports that glucocorticoids enhance tran-
scription unspecifically. Second, the CMV promoter is consti-
tutive, not glucocorticoid-dependent and very strong [13-15]. 
On the other hand, it is possible that glucocorticoids improve 
the cell's capability of endocytosis. However, endocytosis of 
the exogene takes place within 3 h from exposure to the 
DNA-vehicle complex, and small amounts of steroids cannot 
influence cellular metabolism by GR-mediated events quickly 
enough to bear any influence on this process. To avoid these 
potential problems, we incubated the cells with cortisol only 
during the 4 h exposure to DNA, and removed it from the 
cells right after the transfection by rinsing extensively with 
PBS and adding fresh medium. Exposure of cells to cortisol 
for only 4 h does not result in any measurable glucocorticoid-
dependent gene transcription. In fact, exposure of Kiki cells 
[16] to dexamethasone for only 4 h is insufficient to induce 
any measurable glucocorticoid-dependent expression of ß-ga-
lactosidase (data not shown). Kiki cells are a permanent cell 
line derived from 3Y1 cells, and carry the lacZ reporter gene 
under the control of the mouse mammary tumour virus 
(MMTV) promoter, a strong promoter that contains essential 
glucocorticoid-responsive elements [17-19]. Under these con-
ditions, steroids must thus exert their effect on what happens 
to the exogene only after internalisation. If more cells can be 
transfected, it is very likely that the activated glucocorticoid 
receptor facilitates or accelerates nuclear transport. 
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The percentage of cells expressing ß-galactosidase was as-
sessed microscopically after fixation and staining with X-gal. 
As shown in Fig. 2, the presence of cortisol increases the 
number of transfected cells at least 2-fold. The effect is not 
due to an alteration in the cell membrane 's properties in pres-
ence of a lipophilic agent like a steroid, because cortisone does 
not improve transfection. The increased transfection efficiency 
is therefore specifically dependent on steroid activity. F o r the 
reasons given above, the increase in the number of cells that 
express the exogene is not due to unspecific enhancement of 
transcription. Taken together, these data imply that in the 
presence of an active l lß -hydroxy glucocorticoid, more cells 
become competent to transfer transfected D N A into their 
nucleus. 
The positive effect of cortisol on transfection efficiency is 
dose-dependent (Fig. 3). The window of active concentrations 
is unusually narrow, starting with 1 n M and reaching a pla-
teau with 2 n M , which is in the range of the dissociation 
constant of glucocorticoids with the glucocorticoid receptor 
[20-23]. Higher concentrations of steroids do not further im-
prove transfection efficiency. In addition, the glucocorticoid 
antagonist RU486 reduces the effect of cortisol (Fig. 4). 
3.3. 11 ß-glucocorticoids enhance transfection efficiency of 
HeLa cells through the GR 
The question that remained to be answered was, does cor-
tisol increase the efficiency of transfection in cells other than 
rat 3Y1? We tested the effect of cortisol, in presence and 
absence of the antagonist RU486, on rat 3Y1 cells and human 
HeLa cells. The latter do not express high levels of glucocor-
ticoid receptors, and in this regard are representative of more 
common cell lines. As shown in Fig. 4, cortisol enhances the 
transfection efficiency of HeLa cells as well as 3Y1 cells, and 
this effect is reduced by the addition of RU486. 
Fig. 4. Cortisol enhances transfection efficiency of 3Y1 and HeLa 
cells through the glucocorticoid receptor. Five μg of CMV-lacZ 
were incubated with no addition, 20 nM cortisol, or 20 nM 
cortisol + 20 μΜ RU486 and transfected to 3Y1 and HeLa cells by 
the PEI method. Transfection efficiency of each sample is repre-
sented as the percent of control. The results represent the mean± 
S.E.M. (n = 5). 
and species, this observation is important for all those who 
wish to improve D N A delivery to cells. 
Acknowledgements: A.G.F.B. and A.G.R. contributed equally to this 
work. We gratefully acknowledge S. Rusconi and M. Ceppi for help-
ful discussions. This work was supported by grant 4037-044802 from 
the Swiss National Foundation. 
References 
3.4. Conclusion 
In conclusion, we have observed that physiological concen-
trations of cortisol, administered to the cells during transfec-
tion, increases the chances of effective D N A uptake in rat 3Y1 
cells and human HeLa cells. The effect is dependent on steroid 
activity and is probably due to increased nuclear translocation 
of the transfected D N A . Because glucocorticoid receptors are 
essentially ubiquitous, both with regard to tissue distribution 
Fig. 3. Dose dependency of cortisol. Increasing amounts of cortisol 
in the nM range were incubated with 5 μg CMV-lacZ plasmid 
DNA and transfected to 3Y1 cells by the polyethyleneimine method. 
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